Ultragenyx Pharma (RARE) Prices 4.44M Share Common Offering at $90/Sh

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the pricing of its underwritten public offering of 4,444,444 shares of its common stock at a price to the public of $90.00 per share resulting in gross proceeds of $400 million, before underwriting discounts. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 666,666 shares of the company's common stock at the public offering price, less the underwriting discount.

The offering is expected to close on or about November 2, 2020, subject to satisfaction of customary closing conditions. J.P. Morgan, Goldman Sachs & Co. LLC, BofA Securities, and Cowen are acting as joint book-running managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became automatically effective on February 21, 2018. This offering is being made solely by means of prospectus supplement and accompanying prospectus.

You May Also Be Interested In

• CNH Industrial Capital prices $600 million in notes due 2031
• CopperTech Metals launches IPO roadshow on NYSE at $16-$18 per share
• Deep Fission raises $40M in public offering on Nasdaq